bluebird bio and Celgene Corporation Announce Updated Clinical Results from Ongoing First-in-Human Multicenter Study of bb2121 Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple ...
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Business Wire
– 100% of the 15 evaluable patients in active dose cohorts (doses above 50 x 106) achieved an objective response; overall response rate (ORR) across all cohorts (n=18) is 89% – – 73% of evaluable patients in active dose cohorts achieved a very good partial response (VGPR) or better; 27% complete response (CR) rate across active dose cohorts – – All patients tested for minimal residual disease (MRD) status (n=4) were found to be MRD-negative – – No disease progression has been observed in active dose cohorts as of May 4, 2017 data cut-off; range of follow-up was 8 to 54 weeks – – No dose-limiting toxicities have been observed – – bluebird to host event with live webcast, Monday, June 5, 6:30 p.m. CT – CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ:BLUE), and Celgene Corporation (NASDAQ:CELG) today announced that updated resul
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact Levi & KorsinskyAccesswire
- BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action LawsuitAccesswire
- Lost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyAccesswire
- BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!GlobeNewswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- 3/26/24 - Form 8-K
- BLUE's page on the SEC website